Filing summary
Entity and period: The supplied filing is TapImmune Inc.’s Form 10-K for the fiscal year ended December 31, 2016—not a filing identified as Marker Therapeutics, Inc. The company traded as TPIV. This is an annual report; quarterly figures are not separately provided here.
Business context
TapImmune was a clinical-stage immuno-oncology company developing peptide vaccines TPIV 200 (Folate Receptor Alpha) and TPIV 100/110 (HER2/neu), plus preclinical Polystart DNA-expression technology. It reported no product revenue or approved products. Its strategy was to advance vaccine candidates through Phase II, pursue partnerships for later development, and continue Polystart research.
Financial performance and position
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $3.800 million | $1.711 million |
| General and administrative expense | $4.692 million | $4.448 million |
| Operating loss | $8.492 million | $6.159 million |
| Net loss | $2.455 million | $34.066 million |
| Net cash used in operating activities | $6.510 million | $4.343 million |
| Cash at year-end | $7.851 million | $6.577 million |
| Working capital | $6.185 million | $(21.360) million |
Margins are not meaningful because the company had no revenue. The lower reported net loss in 2016 primarily reflects a $5.940 million gain from changes in warrant-liability fair value, compared with a $27.873 million loss in 2015; this was a non-cash, financing-instrument accounting effect, not an improvement in operating performance. The company recorded $231,000 in grant income for clinical supplies.
Total liabilities were $1.737 million at year-end, including $1.225 million in accounts payable and accrued liabilities, $492,000 in research agreement obligations, and $5,000 in promissory notes. There was no material conventional long-term debt reported. Financing activities provided $7.785 million in 2016, including $6.0 million from warrant exercises and approximately $3.1 million gross proceeds from private placements; cash use remained dependent on financing.
Changes versus prior year
- R&D expense more than doubled, attributed to increased internal research and licensing-related development activity; G&A also increased modestly.
- Operating loss widened, while net loss fell sharply because of the warrant-liability fair-value swing and warrant amendments that moved most such liabilities into equity.
- Working capital improved substantially from a deficit to positive $6.185 million, chiefly after equity financing and warrant exercises.
- Common shares outstanding increased from 5.883 million to 8.421 million, alongside significant warrants and options. The filing reports approximately 5.492 million options and warrants outstanding in one disclosure; the warrant note separately reports 5.059 million warrants.
Outlook, risks and unusual items
- Management said existing cash was expected to fund operations through the end of 2017, but additional capital was required and no committed financing source was available. The auditor’s report raised substantial doubt about the company’s ability to continue as a going concern.
- TPIV 200 Phase II studies were underway or planned in triple-negative breast cancer and ovarian cancer. A 280-patient Mayo Clinic trial was expected to receive $13.3 million in U.S. Department of Defense grant funding; TapImmune planned to provide vaccine and manufacturing support. The company also co-funded a 40-patient ovarian cancer study combining TPIV 200 with AstraZeneca’s durvalumab.
- Management anticipated a Phase II HER2/neu program in 2017, subject to regulatory and formulation steps. Polystart remained preclinical. These are plans, not assured milestones or guidance.
- Key risks include clinical and regulatory failure, limited cash runway and further dilution, reliance on Mayo and third-party manufacturers, licensing and patent risks, competition, and the need to establish commercial capabilities. The company also disclosed ineffective disclosure controls and five material weaknesses in internal control over financial reporting; remediation was ongoing.
- In August 2016, warrant amendments involved issuing 750,000 additional shares and one million new warrants, while $15.465 million of warrant liabilities was reclassified to equity. These transactions materially affected reported earnings, equity and potential dilution.
Important facts for investors to verify
- Confirm the issuer identity: the provided 10-K is for TapImmune Inc., not Marker Therapeutics, Inc.
- Check subsequent cash, financing, operating burn and actual runway against management’s end-of-2017 estimate and the going-concern warning.
- Verify current trial enrollment, protocol status, timelines and funding arrangements; the filing contains differing site-count and trial-status descriptions.
- Reconcile outstanding warrant and option counts, exercise prices, registration-related cash obligations and potential dilution.
- Review progress in remediating the disclosed internal-control weaknesses and any subsequent auditor or filing developments.